2-(2,2-二甲基-1,3,6,2-二噁吖硅杂辛环-6-基)乙基吡啶-4-羧酸酯 | 428507-28-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 2-(2,2-二甲基-1,3,6,2-二噁吖硅杂辛环-6-基)乙基吡啶-4-羧酸酯
• 英文名称: (E)-(dimethylamino-methyleneamino)-acetic acid ethyl ester
• 英文别名: (E)-(dimethylaminomethyleneamino)-acetic acid ethyl ester；(dimethylaminomethyleneamino)acetic acid ethyl ester；(dimethylamino-methylene-amino)-acetic acid ethyl ester；N-(dimethylaminomethylene)-glycine-ethyl ester
• CAS: 428507-28-2
• 化学式: C₇H₁₄N₂O₂
• 分子量: 158.2
• InChiKey: JXVAFPULGWAWJD-SOFGYWHQSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.14
• 重原子数：
  11.0
• 可旋转键数：
  4.0
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  41.9
• 氢给体数：
  0.0
• 氢受体数：
  3.0

反应信息

• 作为反应物：
  描述：

  2-(2,2-二甲基-1,3,6,2-二噁吖硅杂辛环-6-基)乙基吡啶-4-羧酸酯 在 溶剂黄146 、 lithium hexamethyldisilazane 作用下， 以 四氢呋喃 为溶剂， 反应 2.0h， 生成 氟马西尼
  参考文献：
  名称：

  The isolation and use of a benzodiazepine iminochloride for the efficient construction of flumazenil

  摘要：

  The benzodiazepine iminochloride 2 has been isolated, characterized and its reaction with a glycinate enolate synthon investigated resulting in an efficient synthesis of the imidazobenzodiazepine flumazenil. (C) 2003 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0040-4039(03)00078-9
• 作为产物：
  描述：

  甘氨酸乙酯盐酸盐 、 N,N-二甲基甲酰胺二甲基缩醛 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 1.0h， 以81%的产率得到2-(2,2-二甲基-1,3,6,2-二噁吖硅杂辛环-6-基)乙基吡啶-4-羧酸酯
  参考文献：
  名称：

  The isolation and use of a benzodiazepine iminochloride for the efficient construction of flumazenil

  摘要：

  The benzodiazepine iminochloride 2 has been isolated, characterized and its reaction with a glycinate enolate synthon investigated resulting in an efficient synthesis of the imidazobenzodiazepine flumazenil. (C) 2003 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0040-4039(03)00078-9
• 作为试剂：
  描述：

  2-(2,2-二甲基-1,3,6,2-二噁吖硅杂辛环-6-基)乙基吡啶-4-羧酸酯 、 6-chloro-3,4-dihydro-4-methyl-2H-1,4-benzodiazepine-2,5(1H)-dione 在 2-(2,2-二甲基-1,3,6,2-二噁吖硅杂辛环-6-基)乙基吡啶-4-羧酸酯 作用下， 生成 沙马西尼
  参考文献：
  名称：

  Imidazodiazepine derivative

  摘要：

  本发明涉及化合物7-氯-3-(5-二甲基氨甲基-[1,2,4]噁二唑-3-基)-5-甲基-4,5-二氢咪唑[1,5-a][1,4]苯二氮平-6-酮(I)，以及利用式I化合物制备用于治疗焦虑症和/或抗惊厥和/或非镇静性催眠药的药物的用途。

  公开号：

  US06391873B1

文献信息

• Substituted imidazo [1,5-a] pyrimido [5,4-d] [1] benzazepine derivatives
  申请人：——

  公开号：US20030055042A1

  公开（公告）日：2003-03-20

  The present invention is a compound of formula 1 wherein R 1 is halogen or lower alkyl; R 2 is hydrogen, lower alkyl, cycloalkyl, —(CH 2 ) m -phenyl, wherein the phenyl ring may be substituted by lower alkoxy, or is —(CH 2 ) m -indolyl; R 3 is —C(O)O-lower alkyl, —C(O)OH, or a five membered heteroaromatic group, which rings may be substituted by lower alkyl or cycloalkyl; n is 0, 1 or 2; m is 0, 1 or 2; or a pharmaceutically acceptable acid addition salt thereof. Compound I shows high affinity and selectivity for GALA A &agr;5 receptor binding sites.

  本发明是一种化合物，其化学式为 1 其中 R 1 是卤素或较低的烷基; R 2 是氢、较低的烷基、环烷基、—(CH 2 ) m -苯基，其中苯环可能被较低的烷氧基取代，或者是—(CH 2 ) m -吲哚基; R 3 是—C(O)O-较低的烷基、—C(O)OH，或者是一个五元杂环芳基，这些环可能被较低的烷基或环烷基取代; n为0、1或2; m为0、1或2; 或其药学上可接受的酸盐。化合物I显示出对GALA A &agr;5受体结合位点的高亲和力和选择性。
• Substituted imidazo[1,5-A][1,2,4]triazolo[1,5-D][1,4]benzodiazepine derivatives
  申请人：Buettelmann Bernd

  公开号：US20060128691A1

  公开（公告）日：2006-06-15

  The present invention is concerned with substituted imidazo[1,5-a][1,2,4]triazolo[1,5-d][1,4]benzodiazepine derivatives of the formula I wherein R 1 is hydrogen, halogen, lower alkyl, lower alkyl substituted by halogen, lower alkoxy, lower alkoxy substituted by halogen, nitro, cycloalkyl, —O(CH 2 ) m O(CH 2 ) m OH or —C≡C—R′; R 2 is hydrogen or methyl; R 3 is lower alkyl, lower alkyl substituted by halogen, lower alkenyl, lower alkenyl substituted by halogen, lower alkynyl, —(CH 2 ) n -cycloalkyl, —(CR′R″) m —CH 3 , phenyl that is unsubstituted or substituted by halogen, pyridinyl or thienyl each of which is unsubstituted or substituted by lower alkyl, —(CH 2 ) n —NH-cycloalkyl, lower alkenyl-cycloalkyl, lower alkynyl-(CR′R″) m OH, or lower alkynyl-phenyl wherein the phenyl ring is unsubstituited or substituted by halogen, CF 3 , lower alkyl or lower alkoxy; R′ is hydrogen or lower alkyl; R″ is hydrogen, hydroxy or lower alkyl; n is 0, 1 or 2; m is 1, 2 or 3 ; and o is 1 or 2; and pharmaceutically acceptable acid addition salts thereof. This class of compounds have high affinity and selectivity for GABA A α 5 receptor binding sites. Thus, the invention also relates to methods of enhancing cognition and treating cognitive disorders like Alzheimer's disease.

  本发明涉及公式I的取代咪唑[1,5-a][1,2,4]三唑[1,5-d][1,4]苯二氮杂环己烷衍生物，其中R1为氢、卤素、较低烷基、被卤素取代的较低烷基、较低烷氧基、被卤素取代的较低烷氧基、硝基、环烷基、—O(CH2)mO( )mOH或—C≡C—R′；R2为氢或甲基；R3为较低烷基、被卤素取代的较低烷基、较低烯基、被卤素取代的较低烯基、较低炔基、—( )n-环烷基、—(CR′R″)m—CH3、苯基（未取代或被卤素取代）、吡啶基或噻吩基，每种基未取代或被较低烷基取代、—( )n—NH-环烷基、较低烯基-环烷基、较低炔基-(CR′R″)mOH或较低炔基-苯基，其中苯环未取代或被卤素、CF3、较低烷基或较低烷氧基取代；R′为氢或较低烷基；R″为氢、羟基或较低烷基；n为0、1或2；m为1、2或3；o为1或2；及其药学上可接受的酸盐。这类化合物对GABA A α5受体结合位点具有高亲和力和选择性。因此，该发明还涉及增强认知和治疗像阿尔茨海默病这样的认知障碍的方法。
• Substituted imidazo[1,5-a][1,2,4]triazolo[1,5-d][1,4]benzodiazepine derivatives
  申请人：Knust Henner

  公开号：US20060079507A1

  公开（公告）日：2006-04-13

  The present invention is concerned with a method of treating a disease selected from the group consisting of cognitive disorders, anxiety, Alzheimer's disease, and schizophrenia comprising administering a therapeutically effective amount of a substituted imidazo[1,5-a][1,2,4]triazolo[1,5-d][1,4]benzodiazepine derivatives of the following formula wherein R 1 is halogen, lower alkyl, lower alkynyl, cycloalkyl, lower alkoxy, OCF 3 , —NHR, —NHC(O)R or —NHSO 2 R; R 2 is hydrogen, methyl or aryl which is unsubstituted or substituted by one or two substituents selected from the group consisting of halogen and lower alkoxy; R 3 is hydrogen, lower alkyl, lower alkenyl, cycloalkyl, lower alkoxy, —O(CH 2 ) n+1 —O-lower alkyl, —(CH 2 ) n -aryl which is optionally substituted by lower alkyl or halogen, heteroaryl, —NHR, —N(R) 2 , wherein each R can be the same or different, —NHCH 2 C≡CH, or pyrrolidin-1-one; R is hydrogen, lower alkyl, lower alkyl substituted by halogen, heteroaryl, —(CH 2 ) n O-lower alkyl, —NH-lower alkyl, cycloalkyl or aryl, and n is 0, 1, 2 or 3; and with their pharmaceutically acceptable acid addition salts. The invention also provides novel compounds of formula I-A and pharmaceutical compositions containing them. The most preferred indication is Alzheimer's disease.

  本发明涉及一种治疗从认知障碍、焦虑、阿尔茨海默病和精神分裂症中选择的疾病的方法，包括给予下列公式的取代咪唑[1,5-a][1,2,4]三唑[1,5-d][1,4]苯二氮䓬啉衍生物的治疗有效量：其中R1是卤素、较低烷基、较低炔基、环烷基、较低烷氧基、OCF3、—NHR、—NHC(O)R或—NHSO2R；R2是氢、甲基或芳基，未取代或由卤素和较低烷氧基中选择的一种或两种取代基取代；R3是氢、较低烷基、较低烯基、环烷基、较低烷氧基、—O(CH2)n+1—O-较低烷基、—( )n-芳基，可由较低烷基或卤素取代，杂芳基、—NHR、—N(R)2，其中每个R可以相同也可以不同，—NH C≡CH，或吡咯烷酮；R是氢、较低烷基、由卤素取代的较低烷基、杂芳基、—( )nO-较低烷基、—NH-较低烷基、环烷基或芳基，n为0、1、2或3；以及其药学上可接受的酸盐。该发明还提供了公式I-A的新化合物和含有它们的药物组合物。最受欢迎的适应症是阿尔茨海默病。
• Halogen substituted imidazol[1,5-A][1,2,4]triazolo[1,5-D][1,4]benzodiazepine derivatives
  申请人：Knust Henner

  公开号：US20060084801A1

  公开（公告）日：2006-04-20

  The invention relates to halogen substituted imidazo[1,5-a][1,2,4]triazolo[1,5-d][1,4]benzodiazepine derivatives of formula I wherein R 1 , R 2 , R 3 , R 4 and n are as defined in the specification and to pharmaceutically acceptable acid addition salts thereof. The compounds can be used as a cognitive enhancer or for the treatment of cognitive disorders, anxiety, Alzheimer's disease and schizophrenia.

  该发明涉及公式I中卤代咪唑[1,5-a][1,2,4]三唑[1,5-d][1,4]苯二氮平衍生物，其中R1、R2、R3、R4和n如规范中定义，并且其药学上可接受的酸盐。这些化合物可用作认知增强剂或用于治疗认知障碍、焦虑、阿尔茨海默病和精神分裂症。
• Substituted imidazo-[1,5-a][1,2,4]triazolo[1,5-d][1,4] benzodiazepine derivatives
  申请人：Buettelmann Bernd

  公开号：US20070082890A1

  公开（公告）日：2007-04-12

  The present invention is concerned with substituted imidazo[1,5-a][1,2,4]triazolo[1,5-d][1,4]benzodiazepine derivatives of the following formula wherein the definition of substituents is described in the claims. This class of compounds shows high affinity and selectivity for GABA A α5 receptor binding sites and might be useful as a cognitive enhancer or for the treatment of cognitive disorders like Alzheimer's disease.

  本发明涉及以下式的取代咪唑[1,5-a][1,2,4]三唑[1,5-d][1,4]苯二氮䓬啉衍生物，其中取代基的定义在权利要求中描述。这类化合物对GABA A α5受体结合位点表现出高亲和力和选择性，可能有助于作为认知增强剂或治疗认知障碍如阿尔茨海默病的药物。